# Neurogenomic Sovereignty: A Translational Blueprint for Proactive Global Mental and Neurological Health (Version 2.0) – A Doctors Companion to Act Up! Getting your life back after addiction

## Part I: The Scientific and Clinical Imperative

### Section 1: The Neurochemical Origin of Vulnerability: A Paradigm Shift in Addiction and Mental Health

The global burden of substance use disorders (SUDs) and related mental health conditions represents one of the most significant, and yet poorly addressed, challenges of the 21st century. Conservatively estimated to impose a cost of over $4.5 trillion annually on global healthcare, justice, and social systems, the current paradigm for addressing these conditions is fundamentally reactive, inefficient, and disconnected from the underlying biological realities of the individual.1 Decades of treating addiction and mental illness primarily as behavioral or moral failings have yielded unsustainable costs and unacceptable human suffering. This report posits a necessary and revolutionary paradigm shift: to recognize, diagnose, and treat these conditions at their biochemical root.1

The key to this transformation lies in understanding that vulnerability to neurochemical dysregulation is not a random occurrence but is profoundly influenced by an individual's genetic architecture. By embracing the principles of neurogenomic sovereignty—the right of an individual to understand and manage their own neurochemical landscape—we can move from a model of reactive treatment to one of proactive, personalized prevention, unlocking unprecedented gains in public health and human potential.1

At the heart of an individual's neurological resilience is a critical biochemical axis governed by two key enzymatic systems: methylation, regulated by the enzyme methylenetetrahydrofolate reductase (MTHFR), and catecholamine metabolism, regulated by catechol-O-methyltransferase (COMT). The interplay between these two systems largely determines the brain's capacity to synthesize and clear essential neurotransmitters, manage stress, and maintain homeostatic balance. Disruptions in this axis, such as common polymorphisms in the MTHFR gene (e.g., C677T) or the COMT gene (e.g., Val158Met), create a state of profound neurochemical vulnerability that underlies a wide spectrum of psychiatric conditions, including SUDs.1

An individual with impaired MTHFR function suffers from a "supply-side" deficit, unable to produce enough S-adenosylmethionine (SAMe) to properly synthesize and regulate key neurotransmitters like serotonin and dopamine. If this same individual also has slow COMT function (Met/Met genotype), they face a "demand-side" crisis, with an excess of stimulating catecholamines that their system cannot efficiently clear. This combination places the nervous system in a state of constant neurochemical siege, creating a biological predisposition for the anxiety, emotional dysregulation, and reward-deficiency that so often drives substance-seeking behavior.1 A direct and pernicious consequence of this impaired methylation is the accumulation of the neurotoxin homocysteine, which acts as an agonist at the NMDA receptor, leading to chronic excitotoxicity and neuronal damage. This biochemical state manifests as anxiety, depression, and impulsivity, driving individuals to seek external substances to temporarily correct these underlying imbalances, thus initiating a cycle of dependence and addiction.1 This evidence-based causal chain necessitates a redefinition of addiction not as a behavioral choice, but as a treatable biochemical state rooted in genetic vulnerability.

### Section 2: The Comprehensive Neurogenomic Risk Panel: From Legacy Drugs to Novel Synthetics, Prescription Medications, and Natural Compounds

#### 2.1 The Core Panel: A Unified System for Lifelong Risk Stratification

To translate the scientific understanding of neurochemical vulnerability into a clinically actionable tool, the NeuroSovereign™ Panel has been designed. This comprehensive genomic test provides a one-time, lifetime-informative analysis of an individual's genetic architecture across all key neurochemical pathways. Unlike limited, single-gene tests or consumer-focused ancestry products, this panel is engineered to deliver a holistic and dynamic risk profile, empowering clinicians and individuals to proactively manage neurological health.1

The panel integrates a curated set of genetic markers, grouped by their primary function within the central nervous system, allowing for a coherent interpretation of an individual's unique neurobiological profile. The extensive panel of pharmacogenomic enzymes (e.g., CYP1A2, CYP2D6, CYP3A4, CYP2C9, CYP2C19) is particularly critical, as these enzymes are implicated in the metabolism of nearly every substance class, from opioids and stimulants to psychedelics and prescription medications.2 The panel includes:

* **Methylation & Detoxification:** MTHFR (C677T, A1298C), APOE (ε2/ε3/ε4), GSTP1
* **Dopaminergic System:** COMT (Val158Met), MAOA, MAOB, DRD2, SLC6A3 (DAT1), AKT1, BDNF
* **Serotonergic System:** HTR2A, SLC6A4 (5-HTTLPR)
* **GABAergic System:** GABRA2, GABRB3, GAD1/2, SLC6A1, CACNA2D1
* **Opioid System:** OPRM1, ABCB1
* **Cannabinoid System:** CNR1, FAAH
* **Glutamatergic System:** GRIN2A/2B
* **Pharmacogenomic Enzymes:** CYP1A2, CYP2D6, CYP3A4, CYP2C9, CYP2C19, CYP2E1, ADH1B, ALDH2, ADORA2A, BCHE, FMO3, UGT1A9, UGT1A10, UGT2B7, SLC22A1 (OCT1)

This comprehensive architecture allows for a systems-level assessment of two distinct but interconnected axes of vulnerability: **Neurotransmitter Resilience**, governed by the baseline synthesis and regulation of neurotransmitters (e.g., MTHFR, COMT, MAOA), and **Metabolic Clearance**, governed by the pharmacokinetic fate of a substance once ingested. An individual might possess a resilient baseline neurochemistry but be a CYP2D6 poor metabolizer, making them highly vulnerable to opioid toxicity from prodrugs like codeine or tramadol. The NeuroSovereign™ panel is uniquely designed to assess both axes, providing a complete and actionable profile of an individual's neurogenomic risk.

#### 2.2 Detailed Risk Profiles by Substance Class: A Multi-System Pharmacogenomic Analysis

The power of the NeuroSovereign™ Panel lies in its ability to generate specific, evidence-based risk profiles for a wide array of substances. This moves beyond a generic "addiction risk" score to a nuanced understanding of an individual's specific vulnerabilities across both illicit and prescription medications.

##### 2.2.1 Opioids & Depressants

This class of substances presents a significant public health burden, and their metabolism and effects are heavily influenced by an individual's genetic makeup. A multi-gene analysis reveals a complex "Depressant Vulnerability Phenotype" that integrates receptor sensitivity, metabolic activation, clearance rates, and baseline neurochemistry.

* **Fentanyl & Nitazenes:** These potent synthetic opioids act as agonists of the mu-opioid receptor, encoded by the OPRM1 gene.1 Their metabolism is primarily handled by CYP3A4 and CYP3A5, which convert them to inactive metabolites.1 Nitazenes also undergo metabolism by CYP2D6, CYP2B6, and CYP2C8.1 Transport across the blood-brain barrier, a critical step for CNS effects, is mediated by P-glycoprotein, the product of the  
  ABCB1 gene.1
  + **Genomic Correlations:** Variants in OPRM1 (e.g., A118G) alter receptor sensitivity, affecting dosing requirements and addiction liability.1 Polymorphisms in  
    CYP3A4 (e.g., \*22) and CYP3A5 (e.g., \*3/\*6), which lead to reduced enzyme function, are associated with decreased fentanyl clearance and a heightened risk of fatal overdose.19 Similarly,  
    ABCB1 variants impact transport efficiency, influencing CNS drug concentrations and analgesic response.1 For nitazenes, a  
    CYP2D6 poor metabolizer status presents a dramatic overdose risk.1
* **Codeine & Tramadol:** Both are prodrugs that require metabolic activation by CYP2D6 to exert their primary analgesic effects via mu-opioid receptors.1 Codeine is converted to morphine, and tramadol is converted to the more potent O-desmethyltramadol (M1).
  + **Genomic Correlations:** The CYP2D6 gene is the most critical determinant of response. **Poor Metabolizers (PMs)**, who lack functional CYP2D6 enzymes, experience little to no pain relief, representing a case of therapeutic failure. In stark contrast, **Ultrarapid Metabolizers (UMs)**, who possess multiple copies of the functional gene, rapidly convert these prodrugs into their active forms, leading to dangerously high metabolite levels. This creates a severe risk of morphine or M1 overdose, including life-threatening respiratory depression, a fact underscored by FDA black box warnings and explicit Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines recommending avoidance of these drugs in both PM and UM individuals.1
* **Oxycodone, Hydrocodone & Morphine:** These are direct-acting mu-opioid receptor agonists.1 Their metabolism is complex. Oxycodone and hydrocodone are metabolized by both CYP2D6 (to more potent active metabolites, oxymorphone and hydromorphone) and CYP3A4 (to less active metabolites).1 Morphine is primarily cleared via glucuronidation by the UGT2B7 enzyme into both an active (morphine-6-glucuronide, M6G) and an inactive (morphine-3-glucuronide, M3G) metabolite.119
  + **Genomic Correlations:** CYP2D6 polymorphisms significantly alter the ratio of parent drug to active metabolite for oxycodone and hydrocodone, impacting both efficacy and side effect profiles.1 Variants in  
    UGT2B7 can affect morphine clearance and the M6G/M3G ratio, which influences the overall analgesic response and potential for side effects.120
* **Benzodiazepines (Diazepam, Clonazepam) & Alcohol:** These substances primarily act on the GABAergic system to produce their sedative and anxiolytic effects.1 Diazepam is metabolized by CYP2C19 and CYP3A4, while clonazepam relies mainly on CYP3A4.70 Alcohol metabolism is governed by the ADH1B and ALDH2 enzymes.1
  + **Genomic Correlations:** CYP2C19 poor metabolizers exhibit significantly increased exposure to diazepam, necessitating dose adjustments to avoid excessive sedation.70 Variations in  
    CYP3A4 expression levels are a major determinant of clonazepam plasma concentrations and clearance.74 Variants in GABAergic pathway genes like  
    GABRA2 and GAD1 are strongly associated with alcoholism and binge-drinking behaviors.1

###### Table 1: The NeuroSovereign™ Pharmacogenomic Matrix: Opioids & Depressants

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Gene/Allele | Fentanyl/Nitazenes | Codeine/Tramadol | Oxycodone/Hydrocodone | Morphine | Benzodiazepines/Alcohol |
| **OPRM1 A118G** | Increased reward sensitivity, potential for higher dose requirements and addiction liability.1 | Influences response to active metabolite (morphine), affecting analgesia and side effects.122 | Modulates analgesic response and dose requirements.1 | Key determinant of analgesic efficacy and side effect profile.120 | Increased reward from alcohol, higher risk of dependence.1 |
| **CYP2D6 PM** | High overdose risk for nitazenes metabolized by this pathway.1 | **Therapeutic Failure.** Ineffective analgesia due to lack of conversion to active metabolite. **CPIC Guideline: Avoid Use**.33 | Reduced conversion to more potent metabolites (oxymorphone, hydromorphone), potentially decreasing efficacy.45 | N/A (Not a primary pathway) | N/A |
| **CYP2D6 UM** | N/A | **High Toxicity Risk.** Rapid conversion to active metabolite, leading to risk of overdose/respiratory depression. **CPIC Guideline: Avoid Use**.33 | Increased formation of potent metabolites, potentially increasing analgesia but also side effects.45 | N/A | N/A |
| **CYP3A4/5 PM** | **High Toxicity Risk.** Reduced clearance of parent drug, significantly increasing risk of fatal overdose.19 | N/A | Increased plasma concentrations of parent drug, shifting metabolism towards CYP2D6 pathway, altering metabolite ratios and effects.44 | N/A (Minor pathway) | **High Toxicity Risk.** Reduced clearance of diazepam and clonazepam, leading to excessive sedation.70 |
| **UGT2B7 Variants** | N/A | N/A | N/A | Altered clearance and metabolite ratios (M6G/M3G), impacting analgesic efficacy and side effects.120 | N/A |
| **ABCB1 Variants** | Altered transport across blood-brain barrier, affecting CNS concentrations and analgesic response.1 | N/A | N/A | Associated with morphine response and dose requirements.120 | N/A |
| **GABRA2/GAD1 Variants** | N/A | N/A | N/A | N/A | Strong association with alcoholism, impulsivity, and binge drinking.1 |

##### 2.2.2 Stimulants & Empathogens

This class of substances is characterized by its profound effects on the catecholamine systems (dopamine, norepinephrine) and serotonin. Genetic variability in this domain creates two distinct adverse outcome profiles: a "Stimulant/Psychosis Vulnerability Phenotype" driven by dopamine system genetics, and a "Toxicity/Overdose Vulnerability Phenotype" driven by metabolic clearance genetics.

* **Amphetamine & Methamphetamine:** These classic stimulants increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake transporters (DAT, NET), inhibiting the vesicular monoamine transporter 2 (VMAT2), and inhibiting monoamine oxidase (MAO).124 Metabolism is primarily mediated by CYP2D6, with an additional role for FMO3 in methamphetamine N-oxygenation.2
  + **Genomic Correlations:** The COMT Val158Met polymorphism is paramount; the slow-clearing Met/Met genotype dramatically increases the risk of stimulant-induced psychosis and aggression due to an inability to clear excess dopamine.1 This risk is compounded by variants in  
    AKT1 (rs2494732 C/C).1 Variants in  
    SLC6A3 (DAT1) and DRD2 (Taq1A) are associated with addiction liability and impulsivity.1  
    CYP2D6 polymorphisms alter the dose-effect relationship, with PMs at risk for toxicity and UMs potentially experiencing reduced efficacy.2  
    FMO3 polymorphisms may also alter methamphetamine metabolism.17
* **Cocaine:** A potent serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).131 Its primary metabolic route is hydrolysis via plasma esterases, notably butyrylcholinesterase (BChE). A minor but critical pathway involves N-demethylation by CYP3A4 to the hepatotoxic metabolite norcocaine.8
  + **Genomic Correlations:** Variants in the BCHE gene that reduce enzyme activity can impair cocaine clearance, increasing toxicity. The functional BCHE SNP rs1803274 (AA genotype) has been identified as a risk factor for preferring crack cocaine, a more addictive form of the drug.135  
    CYP3A4 polymorphisms can influence norcocaine formation, with inducers increasing toxicity risk. Certain CYP3A4 variants have been associated with addiction risk in specific populations.10
* **MDMA (Ecstasy):** A potent releaser and reuptake inhibitor of serotonin, as well as dopamine and norepinephrine.4 Its complex metabolism begins with O-demethylenation, primarily by CYP2D6, with contributions from CYP1A2, CYP2B6, and CYP3A4. This is followed by methylation via COMT.1
  + **Genomic Correlations:** CYP2D6 PMs are at a significantly higher risk of neurotoxicity due to impaired clearance.1 Critically, MDMA is a mechanism-based inhibitor of CYP2D6, meaning it can temporarily convert a normal metabolizer into a functional poor metabolizer after repeated doses, a process known as phenocopying. This dynamic creates a substantial risk for poly-substance users, as it can dangerously alter the metabolism of other CYP2D6-dependent drugs.5 Low-activity  
    COMT genotypes (Met/Met, Val/Met) are associated with a greater risk of MDMA-induced hyponatremia, a potentially fatal electrolyte imbalance.138
* **Caffeine:** The world's most ubiquitous psychostimulant, caffeine acts primarily as an antagonist of adenosine A1 and A2A receptors.140 Its metabolism is almost exclusively handled by the CYP1A2 enzyme.3
  + **Genomic Correlations:** The CYP1A2 polymorphism rs762551 is a key determinant of caffeine's effects. The A/A genotype defines "fast metabolizers," who clear caffeine quickly. The A/C and C/C genotypes define "slow metabolizers," who experience prolonged effects, including a greater risk of anxiety, insomnia, and cardiovascular stress from standard doses.3 Variants in the  
    ADORA2A gene, which encodes the adenosine A2A receptor, also modulate individual sensitivity to caffeine's effects on anxiety and performance.1

###### Table 2: The NeuroSovereign™ Pharmacogenomic Matrix: Stimulants & Empathogens

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Gene/Allele | Amphetamine/Methamphetamine | Cocaine | MDMA | Caffeine |
| **COMT Val158Met (Met/Met)** | **Extreme risk of stimulant-induced psychosis, mania, and aggression** due to impaired dopamine clearance.1 | Increased risk of agitation and paranoia. | Heightened risk of anxiety, mania, or challenging experiences.1 | May increase anxiety/jitteriness. |
| **AKT1 (rs2494732 C/C)** | High risk of stimulant-induced psychosis, especially with COMT Met/Met.1 | N/A | Increased risk of psychosis during experience. | N/A |
| **SLC6A3 (DAT1) / DRD2 (Taq1A)** | High addiction liability, compulsive use, poor impulse control.1 | High addiction liability, compulsive use. | N/A | N/A |
| **CYP2D6 PM** | Increased exposure and risk of toxicity.2 | N/A (minor pathway) | **High Neurotoxicity Risk.** Impaired clearance leads to prolonged exposure and increased risk of adverse events.1 | N/A |
| **CYP3A4 Variants** | N/A | Altered formation of toxic metabolite norcocaine; variants associated with addiction risk.8 | Minor metabolic pathway; variants may alter clearance. | N/A |
| **BCHE Variants** | N/A | Impaired metabolism, potential for increased toxicity. rs1803274 associated with crack cocaine preference.135 | N/A | N/A |
| **CYP1A2 (rs762551 A/C, C/C)** | N/A | N/A | Minor metabolic pathway. | **Slow Metabolizer.** Prolonged effects, increased risk of anxiety, insomnia, and cardiovascular stress.3 |
| **ADORA2A Variants** | N/A | N/A | N/A | Modulates individual sensitivity to caffeine's effects on anxiety and performance.1 |

##### 2.2.3 Psychedelics & Dissociatives

This emerging class of therapeutic and recreational substances has a safety and efficacy profile that is profoundly dependent on an individual's genetic architecture. The NeuroSovereign™ panel provides a framework for stratifying two key risks: adverse psychological events (driven by receptor and neurotransmitter genetics) and adverse physiological events (driven by metabolic genetics).

* **LSD & 1P-LSD:** These are potent partial agonists at serotonin 5-HT2A receptors, with additional interactions at dopamine and adrenergic receptors.148 1P-LSD acts as a prodrug, rapidly converting to LSD in the body.151 The primary metabolic enzyme is CYP2D6, with potential minor roles for CYP1A2 and CYP2C9.6
  + **Genomic Correlations:** Polymorphisms in the HTR2A gene (e.g., rs6311, rs6313) are strong predictors of the subjective quality and intensity of the psychedelic experience, including the risk of anxiety and psychosis.1 Variants in the serotonin transporter gene  
    SLC6A4 also modulate anxiety risk.1  
    CYP2D6 PM status results in approximately 75% higher plasma concentrations and a longer half-life, leading to a more intense and prolonged experience with a greater risk of adverse effects.7 The  
    COMT Met/Met genotype confers a heightened risk of anxiety or mania due to potential dopamine overload.1
* **Psilocybin & Psilocin:** Psilocybin is a prodrug for the active compound psilocin, which is a potent agonist at 5-HT2A, 5-HT2C, and 5-HT1A receptors.156 Psilocin metabolism involves multiple pathways: Phase I oxidation by CYP2D6, CYP3A4, and MAO-A, and Phase II glucuronidation by UGT1A9 and UGT1A10.20
  + **Genomic Correlations:** As with LSD, HTR2A polymorphisms are key determinants of subjective effects.1  
    CYP2D6 polymorphisms are hypothesized to alter the acute psychedelic experience, particularly when combined with MAO inhibitors.20 While clinical data is still emerging, genetic variants in  
    UGT1A9 and UGT1A10 could significantly alter the rate of psilocin clearance, affecting the duration and intensity of the experience.21
* **DMT & Ayahuasca:** DMT is a 5-HT2A receptor agonist that also interacts with sigma-1 and trace amine-associated receptors (TAARs).163 Ayahuasca is a brew that combines a DMT-containing plant (  
  *Psychotria viridis*) with a plant containing MAO-A inhibiting harmala alkaloids (*Banisteriopsis caapi*), which makes DMT orally active.163 DMT is rapidly metabolized by MAO-A, with a secondary pathway involving CYP2D6 and CYP2C19.14 The harmala alkaloids themselves are metabolized by CYP2D6.167
  + **Genomic Correlations:** Low-activity MAOA-uVNTR variants would theoretically prolong the effects of inhaled or injected DMT. In the context of ayahuasca, CYP2D6 PMs would have impaired clearance of the harmala alkaloids, leading to prolonged MAO-A inhibition and dramatically increased and extended DMT exposure, elevating the risk of serotonin syndrome and other toxicities.167
* **Mescaline & 2C-B:** Both are phenethylamines that act as 5-HT2A receptor agonists.173 2C-B is metabolized by MAO-A and MAO-B, with a lesser role for CYP450 enzymes.173 Mescaline's metabolism involves oxidative deamination, but it is a poor substrate for MAO and is not metabolized by CYP2D6. Critically, it is a strong substrate for the organic cation transporter 1 (OCT1), encoded by  
  SLC22A1, which mediates its hepatic uptake.175
  + **Genomic Correlations:** Low-activity MAOA variants would increase the potency and duration of 2C-B, heightening the risk of adverse effects.173 For mescaline, genetically determined low-function variants of the  
    SLC22A1 (OCT1) transporter could lead to strong interindividual variations in pharmacokinetics and a higher risk of adverse reactions due to impaired hepatic uptake and clearance.179
* **Ketamine & PCP:** These are dissociative anesthetics that function as non-competitive NMDA receptor antagonists.1 Ketamine is primarily metabolized by CYP3A4 and CYP2B6 to its active metabolite, norketamine.11 PCP metabolism is complex, involving multiple CYPs, with CYP3A4 playing a major role.16
  + **Genomic Correlations:** Polymorphisms in GRIN2B, which encodes an NMDA receptor subunit, (e.g., rs1806201, rs7301328) are associated with ketamine abuse, earlier onset of use, and higher consumption doses.1 Variants in  
    CYP3A4 and CYP2B6 can alter ketamine clearance, affecting both therapeutic efficacy and abuse potential.11

###### Table 3: The NeuroSovereign™ Pharmacogenomic Matrix: Psychedelics & Dissociatives

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Gene/Allele | LSD/1P-LSD | Psilocybin/Psilocin | DMT/Ayahuasca | Mescaline/2C-B | Ketamine/PCP |
| **HTR2A Variants** | **Strongly predicts intensity, quality, and risk of adverse psychological experiences** (anxiety, psychosis).1 | Key determinant of subjective effects; certain variants alter psilocin signaling potency.1 | Key receptor for psychedelic effects.164 | Primary target for psychedelic effects.173 | N/A |
| **COMT Met/Met** | Heightened risk of anxiety, mania, or challenging experiences.1 | Increased risk of anxiety. | N/A | N/A | N/A |
| **CYP2D6 PM** | **Increased intensity/duration.** ~75% higher plasma concentration, longer half-life, greater risk of adverse effects.7 | Hypothesized to alter experience, especially with MAOIs.20 | **High Toxicity Risk (Ayahuasca).** Impaired clearance of harmala alkaloids leads to prolonged MAO-A inhibition and excessive DMT exposure.167 | N/A (Not a primary pathway) | N/A |
| **MAOA Low Activity** | N/A | N/A | Prolonged effects of inhaled/injected DMT; increased toxicity risk with Ayahuasca.181 | Increased potency and duration of 2C-B, higher risk of adverse effects.173 | N/A |
| **UGT1A9/1A10 Variants** | N/A | Potential for altered psilocin clearance, affecting duration and intensity of effects.156 | N/A | N/A | N/A |
| **SLC22A1 (OCT1) Low Function** | N/A | N/A | N/A | **High Risk (Mescaline).** Impaired hepatic uptake leads to higher plasma levels and increased risk of adverse reactions.179 | N/A |
| **GRIN2B Variants** | N/A | N/A | N/A | N/A | **High risk for dissociative psychosis and abuse.** Associated with earlier onset and higher doses of ketamine use.1 |
| **CYP3A4/CYP2B6 Variants** | N/A | N/A | N/A | N/A | Altered clearance of ketamine and PCP, affecting efficacy and abuse potential.11 |

#### 2.3 Proactive Defense: Integrating Emerging Threats and Natural Compounds

A static risk panel is insufficient in a world of constantly evolving drug markets. A key strategic advantage of the NeuroSovereign™ platform is its ability to proactively integrate and provide risk analysis for novel psychoactive substances (NPS) and plant-based compounds as they emerge. This transforms the panel from a static health product into a dynamic public health surveillance and harm reduction platform.1

##### Novel Psychoactive Substances (NPS)

The platform is designed to rapidly incorporate new threats identified by bodies like the UNODC. Risk can be accurately inferred from the genetic markers already in our panel by analyzing the metabolic pathways and receptor targets of new compounds, often based on their structural similarity to known drugs.

* **Synthetic Opioids (Nitazenes):** Vulnerability is dictated by OPRM1 (receptor sensitivity), and toxicity is heavily influenced by metabolic pathways including CYP2D6, CYP2B6, and CYP2C8. A poor metabolizer status for these enzymes confers a dramatically elevated risk of fatal overdose.1
* **Synthetic Cannabinoids (HHC):** Metabolism parallels that of THC, relying on CYP3A4, CYP2C9, and CYP2C19. Individuals with common polymorphisms in these enzymes will experience vastly different psychoactive effects and toxicity.1
* **Muscle Relaxants (Carisoprodol):** This pro-drug is converted to its active metabolite, meprobamate, almost exclusively by the highly polymorphic CYP2C19 enzyme. CYP2C19 poor metabolizers can experience a four-fold increase in exposure, leading to a high risk of severe CNS depression.1
* **Other NPS:** The panel's architecture allows for the assessment of risk for a wide range of emerging phenethylamines (e.g., 25B-NBOH, 2C-B-Fly, 2C-x series), tryptamines (e.g., 4-AcO-DMT), and arylcyclohexylamines (e.g., 3-MeO-PCP) by applying established metabolic principles from their parent compounds.173

##### Plant-Based Psychoactives & Herb-Drug Interactions

A massive and underappreciated area of risk involves the interaction between common herbal supplements and prescription medications. Many "natural" compounds are potent modulators of the same CYP enzymes responsible for drug metabolism, creating a significant potential for adverse events.

* **Kratom (*Mitragyna speciosa*):** Contains the atypical opioid alkaloids mitragynine and 7-hydroxymitragynine. These compounds are metabolized by CYP3A4 and CYP2D6. Critically, they are also potent inhibitors of these same enzymes, creating a high risk for drug-drug interactions with other opioids, benzodiazepines, and antidepressants that share these pathways.28 This mechanism-based inhibition can phenocopy a normal metabolizer into a poor metabolizer, a dynamic that poses a severe risk to poly-substance users.
* **Kava (*Piper methysticum*):** Contains kavalactones, which interact with numerous CYP enzymes, including CYP2C19, CYP2C9, CYP1A2, CYP2D6, and CYP3A4.29 Its use has been associated with hepatotoxicity, which may be linked to specific metabolic pathways and genetic predispositions, particularly in individuals with pre-existing liver conditions or specific CYP polymorphisms.
* **Khat (*Catha edulis*):** Contains the stimulants cathinone and cathine. Khat consumption significantly inhibits CYP2D6 and, to a lesser extent, CYP1A2, CYP2C19, and CYP3A4. The degree of this inhibition is genotype-dependent, with carriers of defective alleles for CYP2C19 or CYP1A2 showing more pronounced effects.30
* **St. John's Wort (*Hypericum perforatum*):** A widely used herbal antidepressant. Its constituent, hyperforin, is a potent ligand for the pregnane X receptor (PXR), a key regulator of CYP3A4 transcription. This makes St. John's Wort a strong inducer of CYP3A4, which can dramatically increase the metabolism and reduce the efficacy of over 50% of all prescription drugs, including oral contraceptives, immunosuppressants, and certain opioids.207

###### Table 4: The NeuroSovereign™ Pharmacogenomic Matrix: Plant-Based Psychoactives & Other Compounds

|  |  |  |  |
| --- | --- | --- | --- |
| Substance/Plant | Primary Bioactive(s) | Key Metabolic/Interaction Genes | Primary Genomic-Mediated Risk |
| **Kratom** | Mitragynine, 7-Hydroxymitragynine | CYP2D6, CYP3A4 | **High DDI Risk.** Potent inhibition of CYP2D6/3A4 can dangerously increase levels of co-administered opioids, benzodiazepines, etc..28 |
| **Kava** | Kavalactones | CYP2C19, CYP2C9, CYP1A2, CYP2D6, CYP3A4 | **Hepatotoxicity & DDI Risk.** Inhibition of multiple CYPs alters metabolism of many drugs. Risk of liver injury may be genotype-dependent.29 |
| **Khat** | Cathinone, Cathine | CYP2D6, CYP1A2, CYP2C19, CYP3A4 | **DDI Risk.** Genotype-dependent inhibition of CYP2D6 and other enzymes alters metabolism of co-administered drugs.30 |
| **Ayahuasca** | DMT, Harmala Alkaloids | MAOA, CYP2D6 | **High Serotonin Toxicity Risk.** CYP2D6 PMs have impaired clearance of harmala alkaloids, leading to prolonged MAO-A inhibition and excessive DMT exposure.167 |
| **St. John's Wort** | Hyperforin | CYP3A4 (via PXR) | **Therapeutic Failure Risk.** Strong induction of CYP3A4 dramatically reduces efficacy of >50% of prescription drugs (e.g., opioids, oral contraceptives).207 |
| **Ephedra** | Ephedrine, Pseudoephedrine | N/A (largely unmetabolized) | Primarily cardiovascular risk (hypertension, arrhythmia), not strongly linked to metabolic genes.211 |
| **Datura/Brugmansia** | Atropine, Scopolamine | Hepatic hydrolysis | Primarily anticholinergic toxicity risk. Metabolism is not primarily via polymorphic CYPs.213 |

This proactive integration of NPS and natural compounds transforms the NeuroSovereign™ platform into a comprehensive Medication and Supplement Safety Platform. This significantly broadens its applicability and market potential beyond SUDs to encompass the vast and growing population of individuals engaged in polypharmacy, whether prescribed or self-selected. This capability addresses a critical unmet need for personalized polypharmacy management, positioning the platform as an invaluable tool for healthcare systems, insurers, and pharmacy benefit managers.

### Section 3: Clinical Application and Precision Intervention Protocols

#### 3.1 The Power of Pre-Methylated Compounds: Bypassing the Genetic Bottleneck

The cornerstone of the intervention protocol is the strategic use of biochemically active, pre-methylated nutrients. This approach is designed to directly bypass the enzymatic weaknesses identified by the genomic panel, delivering essential cofactors in a form the body can immediately utilize.1

* **Folic Acid versus L-Methylfolate (5-MTHF):** Standard folic acid is biologically inactive and requires conversion by the MTHFR enzyme. For the 40-60% of the population with MTHFR polymorphisms, this conversion is inefficient. Supplementing directly with L-methylfolate (5-MTHF) completely bypasses this genetic bottleneck, delivering the active molecule needed to fuel the methylation cycle.1
* **The Direct Role of S-Adenosylmethionine (SAM-e):** SAM-e is the body's universal methyl donor, indispensable for the synthesis of dopamine and serotonin. For individuals with severe methylation impairment, direct supplementation provides immediate support to these vital pathways.1
* **Synergistic B Vitamins:** Methylcobalamin (active B12) works with 5-MTHF to convert toxic homocysteine back into methionine. Pyridoxal-5-Phosphate (P-5-P), the active form of vitamin B6, is a crucial cofactor for clearing homocysteine and synthesizing neurotransmitters.1

This precision approach—using the right form of the right nutrient for the right genotype—is a fundamental departure from generic nutritional advice and is central to the efficacy of the NeuroSovereign™ system.1

#### 3.2 Therapeutic Protocols: A Substance-Specific, Gene-Informed Approach

The integration of extensive pharmacogenomic data allows the NeuroSovereign™ platform to guide not only nutritional support but also prescription drug selection and dosing, using established clinical guidelines as a model for its recommendations. This demonstrates that the core principle of gene-based dosing is not a future concept but a current, evidence-based standard of care for several major drug classes.

* **Leveraging CPIC and DPWG Guidelines:** The platform's recommendations are modeled on the rigorous, evidence-based guidelines published by world-leading consortia, including the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG). These bodies have established clear, actionable protocols for critical gene-drug pairs, such as CYP2D6 with codeine and tramadol, and CYP2C19 with SSRIs like sertraline.33 By automating the application of these proven models, the NeuroSovereign™ platform can significantly enhance medication safety and efficacy.
* **Protocol for Universal MTHFR Variants (Under-Methylators):**
  + **Dietary Guidance:** Maximize intake of natural folates (leafy greens, legumes) and strictly avoid synthetic folic acid from fortified foods.1
  + **Core Supplementation:** L-Methylfolate (1-15 mg/day), Methylcobalamin (1-5 mg/day), and N-Acetylcysteine (NAC) (600-1800 mg/day) to boost glutathione and protect against homocysteine-induced oxidative stress.1
* **Protocol for COMT Met/Met (Slow) Variants (Catecholamine Sensitivity):**
  + **Dietary Guidance:** Focus on magnesium-rich foods (nuts, seeds) as magnesium is a necessary cofactor for the COMT enzyme.1
  + **Core Supplementation:** Avoid high doses of methyl donors (SAM-e, high-dose methylfolate) which can cause overstimulation. Instead, use non-methylated but bioactive B-vitamins like folinic acid and hydroxocobalamin. Supplement with magnesium (200-400 mg/day) and adaptogens like Rhodiola or Ashwagandha to modulate the stress response.1
* **Pharmacogenomic Dosing Protocol Example (Opioids):**
  + For a patient identified as a **CYP2D6 Ultrarapid Metabolizer (UM)**, the protocol will generate a high-priority alert: "AVOID codeine and tramadol. Rapid metabolism to active metabolites creates a high risk of life-threatening toxicity. Preferred alternatives include morphine, hydromorphone, or fentanyl, as their metabolism is not primarily dependent on CYP2D6".33
  + For a patient identified as a **CYP2D6 Poor Metabolizer (PM)**, the alert will state: "AVOID codeine and tramadol. Lack of metabolic activation will result in therapeutic failure (no analgesia). Preferred alternatives include morphine, hydromorphone, or fentanyl".33
* **Pharmacogenomic Dosing Protocol Example (Antidepressants):**
  + For a patient identified as a **CYP2C19 Poor Metabolizer (PM)** prescribed sertraline, the protocol will recommend: "Consider a 50% reduction of the recommended starting dose and titrate to clinical response. Alternatively, select a drug not predominantly metabolized by CYP2C19. Monitor for side effects due to increased drug exposure".37

The inclusion of these established, third-party validated guidelines serves as a powerful proof of concept for the entire NeuroSovereign™ model. It demonstrates that gene-based dosing is not a theoretical construct but a current, evidence-based standard of care, thereby de-risking the venture and accelerating the path to clinical acceptance and reimbursement.

###### Table 5: Summary of Actionable Pharmacogenomic Guidelines (CPIC & DPWG Models)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Gene | Phenotype | Key Drug(s) | Clinical Implication | Actionable Recommendation (Modeled on CPIC/DPWG) |
| **CYP2D6** | **Poor Metabolizer (PM)** | Codeine, Tramadol | Lack of conversion to active metabolite (morphine, M1). | **Therapeutic Failure.** Avoid use. Select alternative analgesic (e.g., morphine).33 |
|  | **Ultrarapid Metabolizer (UM)** | Codeine, Tramadol | Rapid conversion to active metabolite. | **High Toxicity Risk.** Avoid use due to risk of overdose. Select alternative analgesic.34 |
| **CYP2C19** | **Poor Metabolizer (PM)** | Sertraline, Diazepam | Greatly reduced metabolism, leading to higher plasma concentrations. | **High Side Effect Risk.** Consider 50% dose reduction or select alternative drug not metabolized by CYP2C19.37 |
|  | **Ultrarapid Metabolizer (UM)** | Sertraline | Increased metabolism, leading to lower plasma concentrations. | **Potential Therapeutic Failure.** Consider alternative drug. Titrate to effect.37 |
| **CYP3A4/5** | **Poor Metabolizer (PM)** | Fentanyl, Clonazepam, Quetiapine | Reduced clearance, leading to higher plasma concentrations. | **High Toxicity Risk.** Consider dose reduction or alternative drug based on specific guidelines.23 |
| **CYP2B6** | **Poor Metabolizer (PM)** | Bupropion, Methadone | Reduced clearance, altered metabolite ratios. | **Altered Efficacy/Toxicity.** Consider dose adjustment and monitor plasma concentrations.35 |

#### 3.3 Pathways for Clinical Integration

The successful deployment of this model depends on its seamless integration into existing healthcare structures. The following pathways are designed for rapid adoption and maximum impact, leveraging the expanded applications of the panel.

* **Emergency Department (ED) and Crisis Units:** A pre-existing genomic flag in a patient's electronic health record (EHR), potentially via a voluntary public health registry, would be invaluable. A triage nurse could receive an immediate alert, such as: "COMT Met/Met + AKT1 C/C: High risk for stimulant-induced psychosis; avoid ketamine for sedation" or "CYP2D6 UM: Patient is on codeine; high risk for morphine overdose; monitor for respiratory depression".1 This allows for immediate, life-saving adjustments to care.
* **Inpatient Detoxification and Psychiatric Units:** Upon admission, the NeuroSovereign™ panel could become a standard part of the workup. Results would revolutionize discharge planning by stratifying relapse risk and guiding pharmacogenomic decisions. For example, it could predict a poor response to a specific SSRI in a patient with a relevant CYP2C19 or CYP2D6 variant, thus avoiding weeks of ineffective treatment.1
* **Primary Care and Pain Management:** The panel's most powerful preventive application is in primary care. Before the first potentially addictive prescription is written—particularly for opioids—a genomic screen could identify individuals at high risk. A patient with high-risk OPRM1 variants and a CYP2D6 PM status would be a clear candidate for non-opioid pain management strategies or an alternative opioid like morphine whose metabolism is not CYP2D6-dependent.1 The panel can also flag critical herb-drug interaction risks, alerting a physician that their patient's use of St. John's Wort may be rendering their prescribed medication ineffective.207
* **Cost-Benefit Justification:** The economic case for this integration is overwhelming. A one-time panel, costing between $400 and $1,500, is a negligible expense compared to the recurring, catastrophic costs it aims to prevent: a single inpatient overdose admission ($10,000–$30,000), a year of addiction treatment ($60,000+), or years of involvement with the criminal justice system ($20,000+ annually). The return on investment for payers is exponential.1

## Part II: The Venture Proposal: NeuroSovereign Diagnostics & Therapeutics Inc.

### Section 4: The Investment Thesis: A 30x ROI by Addressing a $5 Trillion Global Crisis

This section outlines the compelling, data-driven investment case for NeuroSovereign Diagnostics & Therapeutics Inc. The venture is positioned to capture a vast, underserved market by providing the first truly proactive, scalable, and biologically-grounded solution to the global crisis of neurochemical dysregulation. The integrated platform of precision diagnostics and targeted therapeutics will not only generate substantial financial returns but also create unprecedented societal value.1

The global substance use disorder (SUD) crisis represents a market failure of historic proportions, imposing an annual economic burden of $4.5 to $5 trillion. This market is characterized by reactive, low-efficacy interventions that fail to address the root biological causes of the disease. This failure has created a vacuum—a clear and urgent need for a disruptive, preventive solution. NeuroSovereign Inc. is perfectly positioned to fill this vacuum, supported by powerful, converging market tailwinds in precision genomics, which is projected to grow to $62.34 billion by 2034, and personalized nutrition.1

The value proposition is a proprietary, one-time genomic test providing a lifetime of actionable insights, coupled with a targeted, gene-informed protocol of nutritional support. This closes the loop from diagnosis to intervention, fundamentally shifting the locus of control back to the individual. The business model is a de-risked hybrid B2B/B2G/DTC strategy, leveraging direct-to-consumer sales for immediate cash flow, B2B partnerships with insurers and treatment centers for clinical validation, and large-scale B2G contracts with public health systems for population-level impact and societal ROI. Financial projections indicate a societal ROI greater than 30x, with the potential to save 7–10 million lives and restore 250–400 million Disability-Adjusted Life Years (DALYs) over five years. The ultimate product is not merely a test or a supplement, but a proprietary, ever-expanding dataset linking genomics, biochemistry, interventions, and clinical outcomes on a global scale—a strategic asset of incalculable value.1

### Section 5: Product and Service Architecture

NeuroSovereign Inc.'s commercial success will be driven by a tightly integrated ecosystem of products and services that guide the user seamlessly from diagnosis to action. This closed-loop system is the primary competitive differentiator, creating a defensible platform that delivers superior value to consumers, clinicians, and payers alike.1

* **The NeuroSovereign™ Panel:** A clinical-grade genomic test utilizing a hybrid of Next-Generation Sequencing (NGS) and microarrays for comprehensive and accurate analysis of over 50 target genes. The deliverable includes a clear, intuitive Consumer Report and a detailed Clinician Report with links to scientific literature and specific recommendations. The pricing structure ($499 DTC, $599 B2B) reflects its premium, clinically-actionable nature.1
* **The Methyl-Optimize™ Suite:** A line of custom-formulated, cGMP-certified nutraceuticals designed to address specific biochemical imbalances. Product lines include "Methyl-Foundation" (for MTHFR variants), "SAM-e Boost" (for severe methylation demand), and the highly sophisticated, methyl-free "COMT-Calm" (for slow COMT genotypes sensitive to methyl donors). These will be sold primarily via a monthly subscription service bundled with the test, creating a high-margin, recurring revenue stream.1
* **The NeuroSovereign™ Clinical Decision Support (CDS) Platform (SaaS):** A HIPAA-compliant, EHR-integrated software platform for clinical partners. It will provide at-a-glance risk dashboards, automated alerts for high-risk gene-drug and herb-drug interactions, and evidence-based recommendations for supplement protocols and pharmacogenomic dosing adjustments. Sold via a tiered SaaS licensing model, this platform embeds the entire system into the clinical workflow, creating high switching costs and a durable competitive moat.1

### Section 6: Go-to-Market and Global Rollout Strategy

The successful launch and scaling of NeuroSovereign Inc. will be executed through a strategic, three-phased approach designed to systematically de-risk the venture, using early clinical validation to unlock larger commercial and governmental contracts, ultimately establishing the platform as the global standard for proactive neurological health.1

* **Phase 1 (Years 1-2): Pilot Programs & Early Adopter Validation:** This phase focuses on generating incontrovertible clinical and economic evidence in targeted, high-impact environments. Key partners will include single-payer systems like the U.S. Department of Veterans Affairs (VA) and Tribal Health Services, as well as leading private addiction medicine centers. Concurrently, a targeted Direct-to-Consumer (DTC) launch will build brand credibility and generate early revenue.1
* **Phase 2 (Years 3-4): National Scaling & Payer Integration:** Leveraging data from Phase 1, this phase focuses on achieving significant market penetration and establishing reimbursement pathways. This involves securing large-scale contracts with public health agencies (e.g., SAMHSA, CDC), engaging private payers to establish coverage, and marketing the platform to large employers as a premium wellness benefit. A broad public health awareness campaign will be launched, centered on the message: "Addiction isn’t a choice—it's chemistry".1
* **Phase 3 (Year 5+): Global Expansion & Data Monetization:** With a dominant position established in North America, the final phase focuses on global leadership and leveraging the company's most valuable asset: its data. This involves expanding into key international markets (Europe, Asia-Pacific), forging partnerships with global health organizations (WHO, UNODC), and monetizing the unique, anonymized dataset through R&D partnerships with pharmaceutical companies to accelerate drug development and clinical trial recruitment.1

## Part III: Operational, Risk, and Ethical Frameworks

### Section 7: Supply Chain Fortification and Risk Mitigation

A cornerstone of the NeuroSovereign venture is a resilient and meticulously managed operational backbone, managing two distinct supply chains: one for high-tech diagnostics and another for cGMP-grade nutraceuticals. A proactive, multi-layered risk mitigation strategy is essential for ensuring product quality, operational continuity, and investor confidence.1

The diagnostic supply chain, comprised of reagents, sequencing hardware, and kitting logistics, faces risks from supplier concentration and geopolitical instability. These will be mitigated through a multi-sourcing strategy with geographic diversification and strategic stockpiling. The nutraceutical supply chain, focused on complex compounds like L-methylfolate and SAM-e, faces risks related to manufacturing expertise and quality control. These will be mitigated by securing long-term partnerships with leading cGMP-certified manufacturers, implementing rigorous third-party batch testing, and exploring vertical integration as the company scales. A premium pricing strategy provides the necessary margin to invest in a redundant, high-quality, and secure supply chain, ensuring financial resilience against market shocks.1

### Section 8: Ethical Governance and Data Sovereignty

In the sensitive domains of genomics and mental health, trust is the core asset. NeuroSovereign Inc. is founded on the principle that a proactive, transparent, and user-centric ethical framework is a primary competitive advantage. The approach to the Ethical, Legal, and Social Implications (ELSI) is designed to set a new industry standard.1

This framework will be built to exceed existing regulations like GINA. An independent Ethics Advisory Board composed of bioethicists, genetic counselors, and patient advocates will be established to audit protocols and policies. The informed consent process will be a dynamic, multi-layered, opt-in model, allowing users granular control over how their de-identified data is used for internal R&D or shared with external partners. Data security will be built on a "privacy-by-design" foundation with gold-standard encryption. Crucially, a "High-Privacy" option will be offered, where a user's raw genetic data is permanently erased from company systems after their report is generated, ceding ultimate control to the user and building profound trust. All public health messaging will be carefully crafted to empower, not frighten, rigorously avoiding deterministic language and promoting a sense of self-efficacy. The company name itself—NeuroSovereign—embodies this ethical framework, communicating the core mission to provide individuals with the knowledge and tools to reclaim authority over their own neurochemistry.1

### Section 9: Future Outlook and Next-Generation Applications

While the initial focus on Substance Use Disorders (SUDs) provides the most compelling entry point into the market, the NeuroSovereign™ platform is engineered for a much broader and more ambitious future. The core biological pathways targeted—methylation, detoxification, and catecholamine regulation—are fundamental to a wide spectrum of neurological and psychiatric conditions. The long-term vision is to leverage the validated platform and proprietary dataset to become the global leader in proactive, personalized brain health and wellness.1

Once the platform is established, expansion will systematically target adjacent, high-need indications where the underlying neurobiology shows significant overlap. These include:

* **Attention-Deficit/Hyperactivity Disorder (ADHD):** A disorder of dopamine regulation with established links to DAT1, DRD4, MTHFR, and COMT variants.1
* **Post-Traumatic Stress Disorder (PTSD):** Rooted in the dysregulation of the HPA axis, with key genes like FKBP5 and CRHR1 interacting with MTHFR and COMT variants to predict risk.1
* **Depression and Anxiety:** The link between MTHFR/COMT function, serotonin/dopamine synthesis, and mood disorders is well-established, offering immediate value in guiding adjunctive treatment with L-methylfolate or SAM-e for treatment-resistant depression.1

The ultimate vision extends beyond disease prevention into the larger wellness and human performance market. Future applications include cognitive enhancement, stress resilience for high-pressure professions, and healthy aging protocols to mitigate the risk of age-related cognitive decline, including targeted interventions for individuals with high-risk profiles like APOE ε4. By starting with the most urgent clinical need (SUDs) and systematically expanding, NeuroSovereign Inc. will build the world's most comprehensive platform for understanding and optimizing brain function, catalyzing a global movement toward a future where every individual possesses the tools to achieve and maintain their own neurogenomic sovereignty.1

#### Works cited

1. NeuroGenomic Protocol Final.doc.txt
2. Metabolic pathways of amphetamine | Download Scientific Diagram - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/figure/Metabolic-pathways-of-amphetamine_fig1_358977284>
3. Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing - PubMed Central, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8914174/>
4. The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs - PMC, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC81503/>
5. Human Pharmacology of MDMA - Pharmacokinetics, Metabolism, and Disposition, accessed July 30, 2025, <https://jcami.eu/documents/2004_de_la_torre_MDMA_TDM.pdf>
6. CYP2D6 - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/CYP2D6>
7. Genetic influence of CYP2D6 on pharmacokinetics and acute ..., accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/34035391/>
8. CYP450 interactions between illicit substances and prescription medications, accessed July 30, 2025, <https://cdn.mdedge.com/files/s3fs-public/CP01908040.PDF>
9. MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? - PMC - PubMed Central, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC3495276/>
10. Drug Metabolism - The Importance of Cytochrome P450 3A4 - Medsafe, accessed July 30, 2025, <https://www.medsafe.govt.nz/profs/puarticles/march2014drugmetabolismcytochromep4503a4.htm>
11. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N ..., accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/12065445/>
12. Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review - PMC - PubMed Central, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11275228/>
13. Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series) - PubMed, accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/17067556/>
14. Pharmacokinetics of N,N-dimethyltryptamine in Humans - PMC, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10122081/>
15. Full article: N, N-dimethyltryptamine forms oxygenated metabolites via CYP2D6 - an in vitro investigation - Taylor & Francis Online, accessed July 30, 2025, <https://www.tandfonline.com/doi/full/10.1080/00498254.2023.2278488>
16. Biotransformation of phencyclidine - PubMed, accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/3914938/>
17. Methamphetamine - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/Methamphetamine>
18. www.pharmgkb.org, accessed July 30, 2025, <https://www.pharmgkb.org/pathway/PA166356961#:~:text=Article%3A39879556%5D.-,Metabolism,urine%20%5BArticle%3A39859160%5D.>
19. Fentanyl Pathway, Pharmacokinetics/Pharmacodynamics - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/pathway/PA166356961>
20. Pharmacokinetics of Psilocybin: A Systematic Review - PMC, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC12030428/>
21. In vitro and in vivo metabolism of psilocybin's active metabolite psilocin - PMC, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11089204/>
22. CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms - PubMed Central, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11625447/>
23. Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population - PubMed Central, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8940650/>
24. CYP2D6 - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/hgnc/CYP2D6>
25. Metabolism of phencyclidine by human liver microsomes - PubMed, accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/9152594/>
26. The pharmacokinetics and the pharmacodynamics of cannabinoids - PMC - PubMed Central, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6177698/>
27. Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding - Frontiers, accessed July 30, 2025, <https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.919630/full>
28. Pharmacokinetic and Pharmacodynamic Consequences of Cytochrome P450 3A Inhibition on Mitragynine Metabolism in Rats, accessed July 30, 2025, <https://scholars.uthscsa.edu/en/publications/pharmacokinetic-and-pharmacodynamic-consequences-of-cytochrome-p4>
29. KAVA: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews, accessed July 30, 2025, <https://www.webmd.com/vitamins/ai/ingredientmono-872/kava>
30. Effects of Khat (Catha edulis) use on catalytic activities of ... - CORE, accessed July 30, 2025, <https://core.ac.uk/download/pdf/326809358.pdf>
31. Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product | ClinicalTrials.gov, accessed July 30, 2025, <https://clinicaltrials.gov/study/NCT04392011>
32. The Psychostimulant Khat (Catha Edulis) Inhibits CYP2D6 Enzyme Activity in Humans, accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/26444948/>
33. Codeine Therapy and CYP2D6 Genotype - Medical Genetics Summaries - NCBI Bookshelf, accessed July 30, 2025, <https://www.ncbi.nlm.nih.gov/books/NBK100662/>
34. Tramadol Therapy and CYP2D6 Genotype - Medical Genetics ..., accessed July 30, 2025, <https://www.ncbi.nlm.nih.gov/books/NBK315950/>
35. What is the metabolism of Bupropion (Wellbutrin)? - Dr.Oracle AI, accessed July 30, 2025, <https://www.droracle.ai/articles/118808/metabolism-of-bupropion>
36. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC3763712/>
37. Sertraline (Zoloft)- CYP2C19 - MyDrugGenome, accessed July 30, 2025, <https://www.mydruggenome.org/dgi/sertraline/>
38. Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients - PMC, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6969041/>
39. Study Details | Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product | ClinicalTrials.gov, accessed July 30, 2025, [https://www.clinicaltrials.gov/study/NCT04392011?term=kratom,%20mitragynine&viewType=Table&rank=1](https://www.clinicaltrials.gov/study/NCT04392011?term=kratom,+mitragynine&viewType=Table&rank=1)
40. Role of CYP2B6 pharmacogenomics in bupropion-mediated smoking cessation - PubMed, accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/30578565/>
41. Association of CYP2B6 genetic polymorphisms with bupropion and hydroxybupropion exposure: A systematic review and meta‐analysis | Request PDF - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/publication/356093773_Association_of_CYP2B6_genetic_polymorphisms_with_bupropion_and_hydroxybupropion_exposure_A_systematic_review_and_meta-analysis>
42. CYP3A4 and Pharmacogenomics: A Comprehensive Review - Number Analytics, accessed July 30, 2025, <https://www.numberanalytics.com/blog/cyp3a4-pharmacogenomics-comprehensive-review>
43. CYP3A4∗22 Genotyping in Clinical Practice: Ready for Implementation? - PMC, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8296839/>
44. PharmGKB summary: oxycodone pathway, pharmacokinetics - PMC - PubMed Central, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6602093/>
45. Hydrocodone Pathway, Pharmacokinetics - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/pathway/PA166221421>
46. CYP2C9, CYP3A and CYP2C19 metabolize Δ9-tetrahydrocannabinol to multiple metabolites but metabolism is affected by human liver fatty acid binding protein (FABP1), accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11410521/>
47. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy - PubMed Central, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8249478/>
48. Stereoselective Metabolism of Bupropion by Cytochrome P4502B6 (CYP2B6) and Human Liver Microsomes - PMC, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC3596877/>
49. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants - PubMed Central, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10564324/>
50. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors - PMC - PubMed Central, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4512908/>
51. Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" Problem - PubMed, accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/23444277/>
52. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines - PubMed, accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/17635335/>
53. CYP2D6 Genotype Dependent Oxycodone Metabolism in ..., accessed July 30, 2025, <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0060239>
54. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC2935998/>
55. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone - HUG, accessed July 30, 2025, <https://www.hug.ch/sites/interhug/files/structures/pharmacologie_et_toxicologie_cliniques/documents/04-190a_samerbjp1.pdf>
56. Opioid Metabolism and Effects of Cytochrome P450 | Pain Medicine - Oxford Academic, accessed July 30, 2025, <https://academic.oup.com/painmedicine/article/10/suppl_1/S20/1914905>
57. The Effect of CYP2D6 Drug-Drug Interactions on Hydrocodone Effectiveness - PMC, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4150819/>
58. Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism | Request PDF - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/publication/282049124_Methadone_Pharmacogenetics_CYP2B6_Polymorphisms_Determine_Plasma_Concentrations_Clearance_and_Metabolism?_tp=eyJjb250ZXh0Ijp7InBhZ2UiOiJzY2llbnRpZmljQ29udHJpYnV0aW9ucyIsInByZXZpb3VzUGFnZSI6bnVsbCwic3ViUGFnZSI6bnVsbH19>
59. CYP2B6 GENOTYPE AFFECTS METHADONE DISPOSITION IN CHILDREN AS DEMONSTRATED BY PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING. - Scholars@Duke publication, accessed July 30, 2025, <https://scholars.duke.edu/publication/1433981>
60. Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer? - Taylor & Francis Online, accessed July 30, 2025, <https://www.tandfonline.com/doi/pdf/10.1080/14622416.2024.2430161>
61. Pain polymorphisms and opioids: An evidence based review - Spandidos Publications, accessed July 30, 2025, <https://www.spandidos-publications.com/10.3892/mmr.2018.9792>
62. Clinical Annotation for CYP2D6\*5, CYP2D6\*17; hydrocodone; Pain (level 1A Efficacy), accessed July 30, 2025, <https://www.pharmgkb.org/clinicalAnnotation/1451141900>
63. Annotation of CPIC Guideline for hydrocodone and CYP2D6 - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/guidelineAnnotation/PA166228121>
64. Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance and metabolism - PMC, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4667947/>
65. Study Details | CYP2B6 Polymorphisms in Methadone Disposition - ClinicalTrials.gov, accessed July 30, 2025, [https://clinicaltrials.gov/study/NCT01648283?cond=(EFAVIRENZ,%20POOR%20METABOLISM%20OF)%20OR%20(CYP2B6)&rank=4](https://clinicaltrials.gov/study/NCT01648283?cond=(EFAVIRENZ,+POOR+METABOLISM+OF)+OR+(CYP2B6)&rank=4)
66. Implications of OPRM1 and CYP2B6 variants on treatment outcomes in methadone-maintained patients in Ontario: Exploring sex differences | PLOS One - Research journals, accessed July 30, 2025, <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0261201>
67. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4\*1B and 3A5\*3 for 25 fentanyl cases - PubMed, accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/16419387/>
68. Genetics and Opioids: Towards More Appropriate Prescription in Cancer Pain - PMC, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC7409018/>
69. Pharmacogenomics of oxycodone: a narrative literature review - PMC - PubMed Central, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8050982/>
70. Clinical Impact of the CYP2C19 Gene on Diazepam for the Management of Alcohol Withdrawal Syndrome - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/publication/368269798_Clinical_Impact_of_the_CYP2C19_Gene_on_Diazepam_for_the_Management_of_Alcohol_Withdrawal_Syndrome>
71. diazepam - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/chemical/PA449283/literature>
72. From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice - Frontiers, accessed July 30, 2025, <https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1326776/full>
73. Clinical Impact of the CYP2C19 Gene on Diazepam for the Management of Alcohol Withdrawal Syndrome - PMC - PubMed Central, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9961427/>
74. Optimization of Clonazepam Therapy Adjusted to Patient's CYP3A Status and NAT2 Genotype - PMC, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC5203763/>
75. clonazepam + CYP3A4 - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/combination/PA130,PA449050/literature>
76. Influence of the patients' CYP3A4 expression on clonazepam dose... - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/figure/nfluence-of-the-patients-CYP3A4-expression-on-clonazepam-dose-requirements-a-Dose_fig5_308215248>
77. Olanzapine - StatPearls - NCBI Bookshelf, accessed July 30, 2025, <https://www.ncbi.nlm.nih.gov/books/NBK532903/>
78. Pharmacogenetics of Olanzapine Metabolism | Request PDF - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/publication/255732162_Pharmacogenetics_of_olanzapine_metabolism>
79. Olanzapine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 30, 2025, <https://go.drugbank.com/drugs/DB00334>
80. quetiapine - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/chemical/PA451201>
81. Metabolism of quetiapine in vitro. | Download Scientific Diagram - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/figure/Metabolism-of-quetiapine-in-vitro_fig1_23486958>
82. Quetiapine Pharmacokinetics - Psychopharmacology Institute, accessed July 30, 2025, <https://psychopharmacologyinstitute.com/publication/quetiapine-pharmacokinetics-2111>
83. Risperidone Therapy and CYP2D6 Genotype - Medical Genetics Summaries - NCBI, accessed July 30, 2025, <https://www.ncbi.nlm.nih.gov/books/NBK425795/>
84. risperidone - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/chemical/PA451257>
85. Metabolic pathways of risperidone. CYP = cytochrome P450. - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/figure/Metabolic-pathways-of-risperidone-CYP-cytochrome-P450_fig1_342074386>
86. EFFECTS OF CYP3A4 INHIBITION BY DILTIAZEM ON PHARMACOKINETICS AND DYNAMICS OF DIAZEPAM IN RELATION TO CYP2C19 GENOTYPE STATUS - CiteSeerX, accessed July 30, 2025, <https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=281e1da529d780a95ebcb5657e69ee076722f196>
87. Urinary Diazepam Metabolite Distribution in a Chronic Pain Population - Oxford Academic, accessed July 30, 2025, <https://academic.oup.com/jat/article/38/3/135/797163>
88. Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status - PubMed, accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/11560871/>
89. clonazepam - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/chemical/PA449050>
90. Psychopharmacology and Commonly Encountered Enzymatic Drug-Drug Interactions: Implications on Psychiatric Treatment and Psychopharmaceutical Discontinuation Protocols - Benzodiazepine Information Coalition, accessed July 30, 2025, <https://www.benzoinfo.com/2017/03/21/psychopharmacology-and-commonly-encountered-enzymatic-drug-drug-interactions-implications-on-psychiatric-treatment-and-psychopharmaceutical-discontinuation-protocols/>
91. Clonazepam - StatPearls - NCBI Bookshelf, accessed July 30, 2025, <https://www.ncbi.nlm.nih.gov/books/NBK556010/>
92. Clonazepam: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 30, 2025, <https://go.drugbank.com/drugs/DB01068>
93. CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients - PMC, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10613299/>
94. A Review of the Important Role of CYP2D6 in Pharmacogenomics - MDPI, accessed July 30, 2025, <https://www.mdpi.com/2073-4425/11/11/1295>
95. quetiapine - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/chemical/PA451201/guidelineAnnotation/PA166265421>
96. The Pharmacogenetics of Treatment with Quetiapine - MDPI, accessed July 30, 2025, <https://www.mdpi.com/2673-9879/2/3/18>
97. Annotation of DPWG Guideline for risperidone and CYP2D6 - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/guidelineAnnotation/PA166104943>
98. Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/publication/363851850_Association_between_CYP2C19_and_CYP2B6_phenotypes_and_the_pharmacokinetics_and_safety_of_diazepam>
99. Hepatic, Extrahepatic and Extracellular Vesicle Cytochrome P450 2E1 in Alcohol and Acetaminophen-Mediated Adverse Interactions and Potential Treatment Options - MDPI, accessed July 30, 2025, <https://www.mdpi.com/2073-4409/11/17/2620>
100. High Levels of Cytochrome P4503A43 in Brain and Metabolism of Anti-Anxiety Drug Alprazolam to Its Active Metabolite | PLOS One - Research journals, accessed July 30, 2025, <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0002337>
101. Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype - Medical Genetics Summaries, accessed July 30, 2025, <https://www.ncbi.nlm.nih.gov/books/NBK425165/>
102. Benzodiazepine Pharmacology and Central Nervous System–Mediated, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC3684331/>
103. Bromazepam: Uses, Interactions, Mechanism of Action - DrugBank, accessed July 30, 2025, <https://go.drugbank.com/drugs/DB01558>
104. Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route - PubMed, accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/33750027/>
105. Fentanyl: Uses, Interactions, Mechanism of Action - DrugBank, accessed July 30, 2025, <https://go.drugbank.com/drugs/DB00813>
106. www.cdc.gov, accessed July 30, 2025, <https://www.cdc.gov/niosh/ershdb/emergencyresponsecard_29750022.html#:~:text=Fentanyl%20selectively%20binds%20to%20and,cancer%20pain%20or%20in%20anesthesia.>
107. The Rise of Fentanyl: Molecular Aspects and Forensic Investigations, accessed July 30, 2025, <https://www.mdpi.com/1422-0067/26/2/444>
108. Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl ..., accessed July 30, 2025, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940650/>
109. Clinical Pharmacogenetics Implementation Consortium (CPIC ..., accessed July 30, 2025, <https://cpicpgx.org/content/guideline/publication/codeine/2012/22205192.pdf>
110. Annotation of CPIC Guideline for codeine and CYP2D6 - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/guidelineAnnotation/PA166104996/annotation>
111. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid ther, accessed July 30, 2025, <https://cpicpgx.org/content/guideline/publication/opioids/2020/CPIC_opioids_PREPRINT.pdf>
112. Annotation of CPIC Guideline for tramadol and CYP2D6 - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/guidelineAnnotation/PA166228101>
113. CPIC Guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy, accessed July 30, 2025, <https://files.cpicpgx.org/data/guideline/publication/opioids/2020/33387367-supplement.pdf>
114. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy - PubMed, accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/33387367/>
115. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update - PubMed, accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/24458010/>
116. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype - PubMed Central, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC3289963/>
117. Considerations for the Utility of the CPIC Guideline for CYP2D6 Genotype and Codeine Therapy - PubMed, accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/25770140/>
118. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype - PubMed, accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/22205192/>
119. Morphine: Uses, Interactions, Mechanism of Action - DrugBank, accessed July 30, 2025, <https://go.drugbank.com/drugs/DB00295>
120. morphine - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/chemical/PA450550>
121. UGT2B7 UDP glucuronosyltransferase family 2 member B7 [ (human)] - NCBI, accessed July 30, 2025, <https://www.ncbi.nlm.nih.gov/gene/7364>
122. Codeine and Morphine Pathway, Pharmacokinetics - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/pathway/PA146123006>
123. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication - PubMed, accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/16819548/>
124. Amphetamine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 30, 2025, <https://go.drugbank.com/drugs/DB00182>
125. www.ncbi.nlm.nih.gov, accessed July 30, 2025, <https://www.ncbi.nlm.nih.gov/books/NBK556103/#:~:text=Mechanism%20of%20Action,-Amphetamine%20is%20a&text=Once%20inside%20the%20presynaptic%20terminal,necessary%20for%20vesicular%20transporter%20function.>
126. Metamfetamine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 30, 2025, <https://go.drugbank.com/drugs/DB01577>
127. Amphetamine - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/Amphetamine>
128. Annotation of FDA Label for amphetamine and CYP2D6 - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/labelAnnotation/PA166182730>
129. Genetic polymorphisms of human flavin-containing monooxygenase ..., accessed July 30, 2025, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213907/>
130. Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives - PMC, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC2213907/>
131. Cocaine - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/Cocaine>
132. Cocaine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 30, 2025, <https://go.drugbank.com/drugs/DB00907>
133. Major and Minor Metabolites of Cocaine in Human Plasma following Controlled Subcutaneous Cocaine Administration, accessed July 30, 2025, <https://academic.oup.com/jat/article-pdf/30/8/501/2110685/30-8-501.pdf>
134. BCHE gene: MedlinePlus Genetics, accessed July 30, 2025, <https://medlineplus.gov/genetics/gene/bche/>
135. Butyrylcholinesterase genetic variants: association with cocaine ..., accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/24312228/>
136. Effects of CYP3A4 Polymorphisms on Drug Addiction Risk Among the Chinese Han Population - Frontiers, accessed July 30, 2025, <https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2019.00315/full>
137. Understanding MDMA and Empathogenic Drugs - Georgia Addiction Treatment Center, accessed July 30, 2025, <https://georgiaaddictiontreatmentcenter.com/2024/11/21/understanding-mdma-and-empathogenic-drugs/>
138. Ecstasy (MDMA)-induced hyponatraemia is associated with genetic ..., accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/22303032/>
139. Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT) | PLOS One, accessed July 30, 2025, <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0047599>
140. Pharmacokinetic and Pharmacodynamic Effects of Caffeine - EFSA, accessed July 30, 2025, <https://www.efsa.europa.eu/sites/default/files/event/documentset/150305-p09.pdf>
141. (PDF) A COMPREHENSIVE REVIEW ON PHARMACOLOGICAL POTENTIALS OF CAFFEINE - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/publication/377260182_A_COMPREHENSIVE_REVIEW_ON_PHARMACOLOGICAL_POTENTIALS_OF_CAFFEINE>
142. What is the mechanism of Caffeine? - Patsnap Synapse, accessed July 30, 2025, <https://synapse.patsnap.com/article/what-is-the-mechanism-of-caffeine>
143. pmc.ncbi.nlm.nih.gov, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8914174/#:~:text=Caffeine%20is%20almost%20exclusively%20metabolized,additional%20products%20theobromine%20and%20theophylline.>
144. Coffee, ADORA2A, and CYP1A2: the caffeine connection in ..., accessed July 30, 2025, <https://www.pharmgkb.org/literature/6908661/variantAnnotation>
145. The effects of CYP1A2 and ADORA2A genotypes association with acute caffeine intake on physiological effects and performance: A s - Baltic Journal of Health and Physical Activity, accessed July 30, 2025, <https://www.balticsportscience.com/cgi/viewcontent.cgi?article=1732&context=journal>
146. (PDF) The effects of CYP1A2 and ADORA2A genotypes association with acute caffeine intake on physiological effects and performance: A systematic review - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/publication/364077585_The_effects_of_CYP1A2_and_ADORA2A_genotypes_association_with_acute_caffeine_intake_on_physiological_effects_and_performance_A_systematic_review>
147. Coffee; ADORA2A; and CYP1A2: the caffeine connection in Parkinson's disease - Kaiser Permanente Division of Research, accessed July 30, 2025, <https://divisionofresearch.kaiserpermanente.org/publications/coffee-adora2a-and-cyp1a2-the-caffeine-connection-in-parkinsons-disease/>
148. LSD - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/LSD>
149. d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology - MDPI, accessed July 30, 2025, <https://www.mdpi.com/1422-0067/17/11/1953>
150. 2-Minute Neuroscience: LSD - YouTube, accessed July 30, 2025, <https://www.youtube.com/watch?v=WKPMOXD4s-c>
151. 1P-LSD - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/1P-LSD>
152. Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis, accessed July 30, 2025, <https://blossomanalysis.com/papers/genetic-influence-of-cyp2d6-on-pharmacokinetics-and-acute-subjective-effects-of-lsd-in-a-pooled-analysis/>
153. 5-HT2A receptor - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/5-HT2A_receptor>
154. Polymorphism in the Serotonin Receptor 2a (HTR2A) Gene as Possible Predisposal Factor for Aggressive Traits - PMC - PubMed Central, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4319849/>
155. HTR2A Gene Variants and Psychiatric Disorders: A Review of Current Literature and Selection of SNPs for Future Studies | Request PDF - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/publication/6147533_HTR2A_Gene_Variants_and_Psychiatric_Disorders_A_Review_of_Current_Literature_and_Selection_of_SNPs_for_Future_Studies>
156. Full article: Pharmacokinetics of Psilocybin, a Tryptamine Alkaloid in Magic Mushroom (Psilocybe cubensis): A Systematic Review - Taylor & Francis Online, accessed July 30, 2025, <https://www.tandfonline.com/doi/full/10.1080/02791072.2024.2399128?af=R>
157. Psilocin - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/Psilocin>
158. Neural mechanisms underlying psilocybin's therapeutic potential – the need for preclinical in vivo electrophysiology - PubMed Central, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9247433/>
159. Glucuronidation of Psilocin and 4-Hydroxyindole by the Human UDP-Glucuronosyltransferases | Request PDF - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/publication/40685426_Glucuronidation_of_Psilocin_and_4-Hydroxyindole_by_the_Human_UDP-Glucuronosyltransferases>
160. UGT1A9 - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/gene/PA419/literature>
161. Pharmacokinetics of Psilocybin: A Systematic Review - MDPI, accessed July 30, 2025, <https://www.mdpi.com/1999-4923/17/4/411>
162. Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11652822/>
163. Dimethyltryptamine - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/Dimethyltryptamine>
164. 2-Minute Neuroscience: DMT - YouTube, accessed July 30, 2025, <https://www.youtube.com/watch?v=z4UMjpw5a4Y&pp=0gcJCfwAo7VqN5tD>
165. The Clinical Potential of Dimethyltryptamine: Breakthroughs into the Other Side of Mental Illness, Neurodegeneration, and Consciousness - MDPI, accessed July 30, 2025, <https://www.mdpi.com/2813-1851/3/1/7>
166. Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact - MDPI, accessed July 30, 2025, <https://www.mdpi.com/1424-8247/13/11/334>
167. Fast and Slow Metabolizers of Hoasca - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/publication/7613328_Fast_and_Slow_Metabolizers_of_Hoasca>
168. Ayahuasca - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/Ayahuasca>
169. (PDF) Pharmacokinetics of N,N-dimethyltryptamine in Humans - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/publication/370204882_Pharmacokinetics_of_NN-dimethyltryptamine_in_Humans>
170. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. - DrugBank, accessed July 30, 2025, <https://go.drugbank.com/articles/A32558>
171. Effects of CYP2D6 Status on Harmaline Metabolism, Pharmacokinetics and Pharmacodynamics, and a Pharmacogenetics-Based Pharmacokinetic Model - PubMed Central, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC2728464/>
172. Effects of CYP2D6 Status on Harmaline Metabolism, Pharmacokinetics and Pharmacodynamics, and a Pharmacogenetics-Based Pharmacokinetic Model | Request PDF - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/publication/24430863_Effects_of_CYP2D6_Status_on_Harmaline_Metabolism_Pharmacokinetics_and_Pharmacodynamics_and_a_Pharmacogenetics-Based_Pharmacokinetic_Model>
173. 2C-B - Wikiwand, accessed July 30, 2025, <https://www.wikiwand.com/en/articles/2C-B>
174. The forgotten psychedelic: Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin | bioRxiv, accessed July 30, 2025, <https://www.biorxiv.org/content/10.1101/2024.10.22.619393v1.full-text>
175. Mescaline - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/Mescaline>
176. Mescaline - Alcohol and Drug Foundation, accessed July 30, 2025, <https://adf.org.au/drug-facts/mescaline/>
177. 2C-B - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/2C-B>
178. Acute Pharmacological Effects of 2C-B in Humans: An Observational Study - PMC, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC5859368/>
179. Cellular Uptake of Psychostimulants – Are High- and Low-Affinity Organic Cation Transporters Drug Traffickers? - PubMed Central, accessed July 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC7854383/>
180. Genetic Variants of SLC22A1 rs628031 and rs622342 and Glycemic Control in T2DM Patients from Northern Mexico - MDPI, accessed July 30, 2025, <https://www.mdpi.com/2073-4425/16/2/139>
181. MAOA gene: MedlinePlus Genetics, accessed July 30, 2025, <https://medlineplus.gov/genetics/gene/maoa/>
182. Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain therapy - CORE, accessed July 30, 2025, <https://core.ac.uk/download/543607415.pdf>
183. Dissociative Drugs - NYC.gov, accessed July 30, 2025, <https://www.nyc.gov/site/doh/health/health-topics/dissociative-drugs.page>
184. HALLUCINOGENS AND DISSOCIATIVE DRUGS, accessed July 30, 2025, <https://nida.nih.gov/sites/default/files/hallucinogensrrs.pdf>
185. Metabolism and Effects of Ketamine and its Metabolites: Norketamine, Dehydronorketamine, and Hydroxyketamine - Isha Health, accessed July 30, 2025, <https://isha.health/post/metabolism-and-effects-of-ketamine-and-its-metabolites-norketamine-dehydronorketamine-and-hydroxyketamine>
186. How does ketamine affect metabolism and excretion? - Neuroglow, accessed July 30, 2025, <https://neuroglow.com/ketamine-metabolism-and-excretion/>
187. Structures of PCP and its metabolites. | Download Scientific Diagram - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/figure/Structures-of-PCP-and-its-metabolites_fig1_7442135>
188. GRIN2B Gene Polymorphism in Chronic Ketamine Users | Request PDF - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/publication/338693738_GRIN2B_Gene_Polymorphism_in_Chronic_Ketamine_Users>
189. GRIN2B Gene Polymorphism in Chronic Ketamine Users - PubMed, accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/31957106/>
190. 25B-NBOH - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/25B-NBOH>
191. 2C (psychedelics) - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/2C_(psychedelics)>
192. 3-MeO-PCP - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/3-MeO-PCP>
193. 4-AcO-DMT - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/4-AcO-DMT>
194. 4-acetoxy DMT (hydrochloride) - Analytical Standards - CAT N°: 14056 - Bertin bioreagent, accessed July 30, 2025, <https://www.bertin-bioreagent.com/4-acetoxy-dmt-hydrochloride/>
195. 3-HO-PCP - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/3-HO-PCP>
196. Mitragynine - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/Mitragynine>
197. CYP2D6 — Knowledge Hub - Genomics Education Programme, accessed July 30, 2025, <https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/cyp2d6/>
198. Kratom Alkaloids: Interactions With Enzymes, Receptors ... - Frontiers, accessed July 30, 2025, <https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.751656/full>
199. An Updated Review on the Psychoactive, Toxic and Anticancer ..., accessed July 30, 2025, <https://www.mdpi.com/2077-0383/11/14/4039>
200. The Pharmacology, Pharmacokinetics, Efficacy, and Adverse Events Associated With Kava | Request PDF - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/publication/325325317_The_Pharmacology_Pharmacokinetics_Efficacy_and_Adverse_Events_Associated_With_Kava>
201. CYP2C19 — Knowledge Hub - Genomics Education Programme, accessed July 30, 2025, <https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/cyp2c19/>
202. How Safe is Kava? Risks and Realities - News-Medical.net, accessed July 30, 2025, <https://www.news-medical.net/health/How-Safe-is-Kava-Risks-and-Realities.aspx>
203. Kava Uses, Benefits & Dosage - Drugs.com, accessed July 30, 2025, <https://www.drugs.com/npp/kava.html>
204. Khat drug profile | www.euda.europa.eu - European Union, accessed July 30, 2025, <https://www.euda.europa.eu/publications/drug-profiles/khat_en>
205. The Psychostimulant Khat (Catha edulis) Inhibits CYP2D6 Enzyme Activity in Humans | Request PDF - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/publication/282659685_The_Psychostimulant_Khat_Catha_edulis_Inhibits_CYP2D6_Enzyme_Activity_in_Humans>
206. Effect of 95% Ethanol Khat Extract and Cathinone on in vitro Human Recombinant Cytochrome P450 (CYP) 2C9, CYP2D6, and CYP3A4 Activity | Request PDF - ResearchGate, accessed July 30, 2025, <https://www.researchgate.net/publication/328200775_Effect_of_95_Ethanol_Khat_Extract_and_Cathinone_on_in_vitro_Human_Recombinant_Cytochrome_P450_CYP_2C9_CYP2D6_and_CYP3A4_Activity>
207. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor | PNAS, accessed July 30, 2025, <https://www.pnas.org/doi/10.1073/pnas.130155097>
208. Influence of Cytochrome CYP3A4-induction by St. John's Wort on the Steady State Pharmacokinetics of Ambrisentan | ClinicalTrials.gov, accessed July 30, 2025, <https://clinicaltrials.gov/study/NCT01311362>
209. Clinical relevance of St. John's wort drug interactions revisited - PubMed, accessed July 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/31742659/>
210. Hyperamylasemia - StatPearls - NCBI Bookshelf, accessed July 30, 2025, <https://www.ncbi.nlm.nih.gov/books/NBK559273/>
211. Ephedra (medicine) - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/Ephedra_(medicine)>
212. Ephedrine - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/Ephedrine>
213. Jimson Weed | myadlm.org, accessed July 30, 2025, <https://myadlm.org/science-and-research/toxin-library/jimson-weed>
214. Alkaloids of the Genus Datura: Review of a Rich Resource for Natural Product Discovery, accessed July 30, 2025, <https://www.mdpi.com/1420-3049/26/9/2629>
215. Datura - Wikipedia, accessed July 30, 2025, <https://en.wikipedia.org/wiki/Datura>
216. Glucose Tolerance Test - StatPearls - NCBI Bookshelf, accessed July 30, 2025, <https://www.ncbi.nlm.nih.gov/books/NBK532915/>
217. sertraline - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/chemical/PA451333/guidelineAnnotation/PA166127639>
218. CPIC® Guideline for Serotonin Reuptake Inhibitor Antidepressants and CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A, accessed July 30, 2025, <https://cpicpgx.org/guidelines/cpic-guideline-for-ssri-and-snri-antidepressants/>
219. accessed December 31, 1969, <https://www.pharmgkb.org/pathway/PA166122513>
220. protease inhibitors - PharmGKB, accessed July 30, 2025, <https://www.pharmgkb.org/chemical/PA451159/variantAnnotation>
221. accessed December 31, 1969, <https://www.pharmgkb.org/pathway/PA166122509>
222. Influence of CYP2B6 genetic variants on plasma and urine ..., accessed July 30, 2025, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763712/>
223. accessed December 31, 1969, <https://www.researchgate.net/publication/282049124_Methadone_Pharmacogenetics_CYP2B6_Polymorphisms_Determine_Plasma_Concentrations_Clearance_and_Metabolism>